Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $35.44M
Last updated: Nov 17, 2026 at 4:17 PM ET
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Statistics
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a market cap of $35.44M and an enterprise value of $30.92M. Its share count is up 121.57% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 12.74% below the market cap, as cash exceeds debt.
| Market Cap | $35.44M |
|---|---|
| Enterprise Value | $30.92M |
| Latest price (Nov 17, 2026) | $0.42 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | September |
Price Statistics
The stock is down 68.66% over 52 weeks and trades 58.42% below its 50-day average.
| Beta (1Y) | 1.72 |
|---|---|
| 52-Week Change | -68.66% |
| 1-Month Change | -59.32% |
| 3-Month Change | -63.84% |
| 6-Month Change | -65.32% |
| Total Return (1Y) | -68.66% |
| Max Drawdown (1Y) | -71.60% |
| Max Drawdown (3Y) | -96.44% |
| Sharpe Ratio (1Y) | -1.78 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $1.01 |
| 200-Day Average | $1.18 |
| 52-Week Range | $0.44 to $1.58 |
| RSI (14 Days) | 11.0 |
| Average Volume (20 Days) | 165.29K |
Financial Position
Current assets cover 19.60x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 19.60x |
|---|---|
| Quick Ratio | 19.60x |
| Debt / Equity | 0.00x |
| Interest Coverage | -722.27x |
Returns and Efficiency
Return on equity is -124.39% and return on assets is -118.05% over the last 12 months.
| Return on Equity (ROE) | -124.39% |
|---|---|
| Return on Assets (ROA) | -118.05% |
| Return on Capital Employed (ROCE) | -124.28% |
Scores
TELO has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$5.69M |
| Pretax Income | -$5.48M |
| Net Income | -$5.48M |
| EBITDA | -$5.47M |
| EBIT | -$5.47M |
| Reported EPS (TTM) | -$0.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.83% of the $4.64M in total assets.
| Cash and Equivalents | $4.52M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.52M |
| Net Cash Per Share | $0.07 |
| Working Capital | $4.40M |
| Shareholder Equity | $4.40M |
| Book Value Per Share | $0.06 |
| Total Assets | $4.64M |
| Total Liabilities | $236.75K |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3 of capital spending, operating cash flow left -$4.57M of free cash flow.
| Operating Cash Flow | -$4.57M |
|---|---|
| Capital Expenditures | $3 |
| Free Cash Flow | -$4.57M |
| FCF Per Share | -$0.06 |
Trailing 12 months through Sep 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TELO
What is TELO's market cap?
Telomir Pharmaceuticals, Inc. Common Stock has a market cap of $35.44M. Its enterprise value, which adds debt and subtracts cash, is $30.92M.
How many shares of TELO are outstanding?
Telomir Pharmaceuticals, Inc. Common Stock has 68.77M shares outstanding. The count is up 121.57% from a year earlier.
Does TELO pay a dividend?
No. Telomir Pharmaceuticals, Inc. Common Stock does not pay a dividend.
How much debt does TELO have?
Telomir Pharmaceuticals, Inc. Common Stock has $0 of total debt and $4.52M of cash and equivalents, a net cash position of $4.52M.
TELO pages: Overview, Charting, Forecast, Financials, Statistics, Competitors